A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal o...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Gynecologic oncology Ročník 151; číslo 3; s. 422 - 427
Hlavní autori:	Monk, Bradley J., Kauderer, James T., Moxley, Katherine M., Bonebrake, Albert J., Dewdney, Summer B., Secord, Angeles Alvarez, Ueland, Frederick R., Johnston, Carolyn M., Aghajanian, Carol
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.12.2018
Predmet:	Adult Aged Aged, 80 and over Antineoplastic Agents, Phytogenic - pharmacology Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical trial Elesclomol Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - pathology Female Humans Hydrazines - pharmacology Hydrazines - therapeutic use Middle Aged Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Paclitaxel - pharmacology Paclitaxel - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - pathology Clinical trial Elesclomol Ovarian cancer
ISSN:	0090-8258, 1095-6859, 1095-6859
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!